YokoyamaandYSDOSLung CancerTsukada H, Yokoyama A, Kurita Y, Isobe H, Watanabe K, Saijyo N. Phase I=II trial of Cisplatin(CDDP), Etoposide(ETP), and Irinotecan(CPT-II) for the treatment of advanced non-small-cell lung cancer(NSCLC): Japan Clinical Oncology Group(JCOG) study 9512. ...
Phase I/II trial of cisplatin (CDDP), etoposide (ETP), and irinotecan (CPT-11) for the treatment of advanced non-small-cell lung cancer (NSCLC). Japan Clin... Objectives The aim of this study was to evaluate the efficacy of adjuvant chemoradiotherapy following surgery in patients with advan...
We have treated unresectable lung cancer patients with CDDP + IFX + VDS for squamous cell carcinoma, and CDDP + IFX + ETP for small-cell lung cancer. Bone marrow toxicity was moderately severe. To lessen toxicity and maintain the schedul... None - 《Lung Cancer》 被引量: 0发表: 1995年...
doi:10.1016/j.etp.2014.10.002BMP-6CisplatinOsteopontinRenalfibrosisThe significance of bone morphogenetic protein (BMP)-6 and osteopontin (OPN) in renal fibrosis is poorly understood. We investigated the expression of BMP-6 and OPN in cisplatin (CDDP; 6 mg/kg, once, i.p.)-induced renal ...
doi: 10.1016/j.etp.2014.10.002. [PubMed: 25467747]Yano, R.; Golbar, H.M.; Izawa, T.; Sawamoto, O.; Kuwamura, M.; Yamate, J. Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis. Exp. Toxicol. Pathol. 2015, 67, 99-...